Chimerix Inc. (NASDAQ:CMRX) – Investment analysts at William Blair lowered their FY2016 earnings per share (EPS) estimates for shares of Chimerix in a research report issued on Monday. William Blair analyst Y. Xu now anticipates that the firm will earn ($1.72) per share for the year, down from their previous forecast of ($1.69). William Blair also issued estimates for Chimerix’s Q4 2016 earnings at ($0.39) EPS, FY2017 earnings at ($2.14) EPS and FY2018 earnings at ($2.69) EPS.

Several other research analysts have also recently weighed in on CMRX. FBR & Co restated a “hold” rating on shares of Chimerix in a research report on Sunday, July 17th. JPMorgan Chase & Co. restated a “hold” rating and issued a $7.00 price objective on shares of Chimerix in a research report on Tuesday, August 9th. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research report on Wednesday, August 10th. Finally, Piper Jaffray Cos. set a $12.00 price objective on shares of Chimerix and gave the stock a “buy” rating in a research report on Thursday, August 18th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $8.32.

Earnings History and Estimates for Chimerix (NASDAQ:CMRX)

Shares of Chimerix (NASDAQ:CMRX) opened at 4.62 on Thursday. The company’s market cap is $213.51 million. Chimerix has a 1-year low of $3.50 and a 1-year high of $42.24. The stock has a 50 day moving average of $4.80 and a 200 day moving average of $4.61.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.02. Chimerix had a negative net margin of 1,451.99% and a negative return on equity of 32.09%.

A number of institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System increased its position in shares of Chimerix by 0.7% in the third quarter. California State Teachers Retirement System now owns 90,116 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 600 shares during the last quarter. Teachers Advisors Inc. increased its position in shares of Chimerix by 0.9% in the second quarter. Teachers Advisors Inc. now owns 69,684 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 610 shares during the last quarter. BlackRock Investment Management LLC increased its position in shares of Chimerix by 0.8% in the third quarter. BlackRock Investment Management LLC now owns 187,449 shares of the biopharmaceutical company’s stock valued at $1,038,000 after buying an additional 1,477 shares during the last quarter. Raymond James & Associates increased its position in shares of Chimerix by 6.9% in the second quarter. Raymond James & Associates now owns 27,083 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 1,757 shares during the last quarter. Finally, BlackRock Advisors LLC increased its position in shares of Chimerix by 19.4% in the third quarter. BlackRock Advisors LLC now owns 22,213 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 3,611 shares during the last quarter. Institutional investors and hedge funds own 66.25% of the company’s stock.

In other Chimerix news, Director John M. Leonard sold 5,000 shares of the stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $5.03, for a total value of $25,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider M Michelle Berrey acquired 22,417 shares of the firm’s stock in a transaction on Monday, August 29th. The stock was purchased at an average price of $4.47 per share, with a total value of $100,203.99. Following the acquisition, the insider now owns 281,238 shares of the company’s stock, valued at approximately $1,257,133.86. The disclosure for this purchase can be found here. Insiders own 10.50% of the company’s stock.

About Chimerix

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

5 Day Chart for NASDAQ:CMRX

Receive News & Stock Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related stocks with our FREE daily email newsletter.